Formulation Development Applications & Studies

  1. Non Animal Origin Squalene For High-Risk Applications 7/21/2025

    Explore an ethical and sustainable alternative to shark-derived squalene that is backed by robust data to deliver identical performance in vaccine formulations without environmental compromise.

  2. Temperature Dependence On Reversed-Phase Separations 7/17/2025

    Column temperature critically affects the reversed-phase separation of fatty acid-modified GLP-1 RAs and impurities. Learn how precise control enhances resolution and reproducibility.

  3. Column Selection For RPLC-UV Impurity Analysis 7/17/2025

    Explore the performance of four column chemistries for RPLC-UV impurity analysis of liraglutide and semaglutide, which offers practical guidance for method development in peptide-based therapeutics.

  4. UPLC-MS/MS Determination Of GLP-1 Analogue 7/17/2025

    Discover a robust, evaporation-free method for analyzing liraglutide in human plasma using LC-MS/MS to ensure high sensitivity, reproducibility, and improved analyte recovery.

  5. Quantification Of Semaglutide With A Reliable Analytical Method 7/17/2025

    Explore a validated LC-MS/MS method for precise Semaglutide quantification in plasma, which features enhanced sensitivity, peak definition, and reproducibility using innovative technologies.

  6. Developing A Quantitative Surrogate Peptide Assay 7/17/2025

    Discover a streamlined LC-MS/MS workflow for Fc-containing therapeutics like dulaglutide to enable precise quantification with LLOQ as low as 1 ng/mL through automated, efficient assay development.

  7. Bioanalytical Quantification Of A Biotherapeutic Peptide 7/17/2025

    Discover a sensitive, selective, and robust LC-MS method for quantifying semaglutide in plasma with advanced sample preparation and detection technologies for accurate results in bioanalytical research.

  8. Use Of Reconstructed Tissue And 3D Printed CT-Based Nasal Casts 7/3/2025

    Reconstructed nasal epithelium and CT-based 3D nasal casts provide more predictive, physiologically relevant models for assessing nasal drug delivery, improving accuracy in formulation development.

  9. N-1 Perfusion High Inoculum Fed-Batch For Reduced COGS And Easy Retrofit 6/30/2025

    Discover a company that tripled productivity and cut costs by optimizing its seed train process to achieve major gains without infrastructure expansion.

  10. Modular Facilities With Smaller Footprint Through Dynamic Perfusion 6/30/2025

    Discover how a top CDMO leveraged dynamic perfusion technology to boost biomanufacturing throughput, cut capital costs, and enable flexible, multi-modality production.